Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease (MTMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03076671
Recruitment Status : Recruiting
First Posted : March 10, 2017
Last Update Posted : November 22, 2019
Sponsor:
Collaborators:
National Institute of Nursing Research (NINR)
University of California, San Francisco
Information provided by (Responsible Party):
University of Colorado, Denver

Tracking Information
First Submitted Date  ICMJE February 7, 2017
First Posted Date  ICMJE March 10, 2017
Last Update Posted Date November 22, 2019
Actual Study Start Date  ICMJE March 1, 2017
Estimated Primary Completion Date March 31, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 6, 2017)
  • Quality of Life Alzheimer's Disease (QOL-AD) [ Time Frame: Up to 48 months ]
    Measures of Quality of Life
  • Zarit Burden of Care Instrument (ZBI) [ Time Frame: Up to 48 months ]
    Measures of Care Partner Distress
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 20, 2019)
  • McGill Quality of Life Questionnaire (MQOL) [ Time Frame: Up to 48 months ]
    Measures of Quality of Life
  • Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Up to 48 months ]
    Measures of mood
  • Edmonton Symptom Assessment Scale (ESAS_PD) [ Time Frame: Up to 48 months ]
    Measures of symptom burden
  • Functional Assessment of Chronic Illness Therapy-Spiritual Wellbeing (FACIT-SP 12 Item) [ Time Frame: Up to 48 months ]
    Measures of spiritual wellbeing
  • Prolonged Grief Questionnaire (PG-12) [ Time Frame: Up to 48 months ]
    Measures of grief (sense of loss)
  • Semi-structured Qualitative Interview [ Time Frame: At 12 months ]
    Measures of participant views on the study including their outcomes and the implementation of this model of community-based palliative care.
  • Montreal Cognitive Assessment (MOCA) [ Time Frame: At baseline ]
    Measures of cognitive function
  • Healthcare Utilization Form [ Time Frame: Up to 48 months ]
    Measures of type and frequency of healthcare utilized
  • Palliative Performance Scale [ Time Frame: Up to 48 months ]
    Measures of Disease Severity
  • Clinical Global Impression of Change [ Time Frame: Up to 48 months ]
    Measures of change in disease burden
  • Treatment Documentation Form [ Time Frame: Up to 48 months ]
    Measures of treatments used for disease management
  • Modified Caregiver Strain Index [ Time Frame: Up to 48 months ]
    Measures of care partner distress
  • Needs at End of Life Screening Tool [ Time Frame: Up to 12 months ]
    Detects and measures needs for end of life
  • Neuropsychiatric Inventory [ Time Frame: Up to 6 months ]
    Measures dementia-related symptoms
Original Secondary Outcome Measures  ICMJE
 (submitted: March 6, 2017)
  • McGill Quality of Life Questionnaire (MQOL) [ Time Frame: Up to 48 months ]
    Measures of Quality of Life
  • Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Up to 48 months ]
    Measures of mood
  • Edmonton Symptom Assessment Scale (ESAS_PD) [ Time Frame: Up to 48 months ]
    Measures of symptom burden
  • Functional Assessment of Chronic Illness Therapy-Spiritual Wellbeing (FACIT-SP 12 Item) [ Time Frame: Up to 48 months ]
    Measures of spiritual wellbeing
  • Prolonged Grief Questionnaire (PG-12) [ Time Frame: Up to 48 months ]
    Measures of grief (sense of loss)
  • Semi-structured Qualitative Interview [ Time Frame: At 12 months ]
    Measures of participant views on the study including their outcomes and the implementation of this model of community-based palliative care.
  • Montreal Cognitive Assessment (MOCA) [ Time Frame: At baseline ]
    Measures of cognitive function
  • Healthcare Utilization Form [ Time Frame: Up to 48 months ]
    Measures of type and frequency of healthcare utilized
  • Palliative Performance Scale [ Time Frame: Up to 48 months ]
    Measures of Disease Severity
  • Clinical Global Impression of Change [ Time Frame: Up to 48 months ]
    Measures of change in disease burden
  • Treatment Documentation Form [ Time Frame: Up to 48 months ]
    Measures of treatments used for disease management
  • Modified Caregiver Strain Index [ Time Frame: Up to 48 months ]
    Measures of care partner distress
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
Official Title  ICMJE More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
Brief Summary This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple systems atrophy (MSA), Lewy Body Dementia (LBD). In September 2018, the study was amended to also include Alzheimer's disease (AD) and related disorders (Frontotemporal Dementia (FTD), Primary Progressive Aphasia (PPA), Vascular Dementia). It will utilize a randomized stepped-wedge design to compare patient and caregiver outcomes between usual care in the community versus usual care augmented by palliative training and telemedicine support to provide other resources (e.g. social work).
Detailed Description

Parkinson's disease (PD) is the second most common neurodegenerative illness affecting approximately 1.5 million Americans and is the 14th leading cause of death in the United States. PD is traditionally described as a movement disorder with characteristic motor symptoms (e.g. tremor). However, more recent research demonstrates the impact of nonmotor symptoms such as pain, depression, and dementia on mortality, quality of life (QOL), nursing home placement and caregiver distress. Regarding models of care for PD, evidence suggests that care including a neurologist results in lower mortality and nursing home placement than care solely from a primary care physician. Unfortunately, there is also significant evidence that many of the needs most important to PD patients and their caregivers (e.g. depression, planning for the future) are poorly addressed under current models of care. Palliative care is an approach to caring for individuals with life-threatening illnesses that focuses on addressing potential causes of suffering including physical and psychiatric symptoms, psychosocial issues and spiritual needs. While developed for cancer patients, palliative care approaches have been successfully applied in other chronic progressive illnesses including heart failure and pulmonary disease. To date there have been minimal attempts to apply these principles to PD although evidence suggests that PD patients' unmet needs under current models of care may be amenable to palliative care. A small but growing cadre of centers offer outpatient palliative care for PD with early evidence of efficacy and a randomized trial of an academic-based outpatient palliative care is underway led by investigators on this proposal. While this work is critical to forwarding this field, further work is needed to provide a model that can be widely disseminated. The current proposal addresses this gap by assessing the effectiveness and feasibility of a novel community-based intervention that empowers community neurology practices to improve care for PD patients and caregivers through palliative care training, coaching and telemedicine resources. The investigators hypothesize that this intervention will improve patient QOL and caregiver burden and will prove feasible and acceptable to community providers. The investigators Specific Aims are to: 1) Determine the a) effectiveness and b) feasibility of a novel community-based outpatient palliative care intervention for PD.; 2) Describe the effects of a this intervention on patient and caregiver costs and service utilization; and 3) Identify opportunities to optimize community-based palliative care for this population by: a) describing patient and caregiver characteristics associated with intervention benefits; and b) through direct patient, caregiver and provider interviews. Innovations of the investigators approach include a novel model of providing disease-specific community-based palliative care not dependent on limited palliative specialist resources, a stepped-wedge trial design and use of telemedicine resources to provide multidisciplinary care. The research is significant because it will create a foundation for future community-based dissemination studies in PD and the broader field of palliative care.

In September 2018, supplemental support from NIH was granted in order to explore outcomes among an Alzheimer's dementia population. Alzheimer's disease (AD) is the most common neurodegenerative illness affecting 10% of adults over age 65. This incurable and relentlessly progressive disease affects approximately 1.5 million Americans and is the 6th leading cause of death in the United States. Care for community-dwelling patients with AD is typically focused on the assessment and pharmacologic management of cognitive and behavioral symptoms, although there is growing recognition of the need to expand care to address other issues, including advance care planning. There is significant evidence that many of the most important needs of the AD patients and their caregivers are poorly addressed under current models of care, including management of medical and psychiatric symptoms (e.g. pain and depression), caregiver support, advance care planning, and spiritual wellbeing. Importantly, while the top goal of care for the majority of patients is avoidance of institutionalization, our current models of care invest more resources in institutionalized patients rather than proactively supporting community-dwelling individuals which may prevent institutionalization and reduce overall healthcare costs. Our supplemental study will thus additionally target this population for a 12-month period.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This is a stepped-wedge design, meaning that during the first year all patients enrolled will continue to receive usual care provided by their neurologist, who is also enrolled in the study. During years 2 and 3, every 6 months, 4-5 neurologists will receive training in supportive and palliative care. The timing of the training will be randomly assigned. Once their neurologist has received training, all of their enrolled patients will be switched to the intervention arm, and be eligible for additional care via telemedicine with the university supportive and palliative care team. During the final year of the study, all the neurologists will have received care, and all of their patients will be in the intervention arm.

On a separate level, we will be evaluating the effects of training on the enrolled neurologists through assessments of palliative skills, knowledge, and attitudes before and after the training, as well as through qualitative interviews.

Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Parkinson Disease
  • Parkinsonism
  • Lewy Body Disease
  • Supranuclear Palsy, Progressive
  • Parkinsonism Vascular
  • Multiple System Atrophy
  • Corticobasal Degeneration
  • Alzheimer Disease
  • Frontotemporal Dementia
  • Primary Progressive Aphasia
  • Vascular Dementia
Intervention  ICMJE Behavioral: Palliative Care
Palliative care training for community neurologists and use of telemedicine for team-based support of patients
Other Name: Supportive Care
Study Arms  ICMJE
  • No Intervention: Standard of Care
    Patients to get usual care from their established neurology care team that is enrolled in the study.
  • Experimental: Standard of Care plus Palliative Care
    Patients to get usual care, augmented by palliative care, provided by their established neurology care team that is affiliated with the study, with additional support provided by the University of Colorado Denver Neurology Palliative Care team.
    Intervention: Behavioral: Palliative Care
  • Experimental: Clinicians
    Clinicians enrolled in the study will receive an 8-hour supportive and palliative care training, followed by monthly coaching and the availability of telemedicine visits for enrolled patients with the university neuro-palliative care team. The unit of randomization is the time when they receive training. Four to five clinical practices will receive training every 6 months during years 2 and 3, at which time all of their enrolled patients will be switched from usual care to the intervention arm.
    Intervention: Behavioral: Palliative Care
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 24, 2017)
632
Original Estimated Enrollment  ICMJE
 (submitted: March 6, 2017)
360
Estimated Study Completion Date  ICMJE March 31, 2021
Estimated Primary Completion Date March 31, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must be fluent English Speakers,
  • Must be over age 18,
  • They must meet United Kingdom (UK) Brain Bank criteria for probable PD, or
  • They must meet standard criteria for

    • progressive supranuclear palsy (PSP),
    • corticobasal degeneration (CBD),
    • multiple systems atrophy (MSA),
    • vascular parkinsonism, or
    • Lewy Body Dementia (LBD)
    • Alzheimer's dementia (AD)
    • Primary progressive aphasia
    • Vascular dementia.
  • Patients must be at high risk for poor outcomes as defined by the Brief Needs Assessment Tool (BNAT) which screens for psychosocial issues, symptoms, and caregiver burden.
  • Caregivers will be identified by asking the patient: "Could (participant) tell us the one person who helps (participant) the most with (participant's) PD outside of clinic?"
  • Caregivers may be self-identified in cases of severe dementia in order to obtain data relevant to this vulnerable and underrepresented group.

Exclusion Criteria:

  • Unable or unwilling to commit to study procedures;
  • Presence of additional chronic medical illnesses which may require palliative services (e.g. metastatic cancer); or
  • Already receiving palliative care or hospice services.
  • Not expecting to continue care with enrolled physician for at least 6 months.

The investigators have purposefully kept our inclusion/exclusion criteria broad to allow for greater generalizability of results and to ensure inclusion of potentially underrepresented and understudied subgroups.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 105 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Christine S Martin 303-724-8885 christine.martin@ucdenver.edu
Contact: Laura Palmer 303-724-8287 laura.palmer@ucdenver.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03076671
Other Study ID Numbers  ICMJE 16-1400
R01NR016037-01A1 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party University of Colorado, Denver
Study Sponsor  ICMJE University of Colorado, Denver
Collaborators  ICMJE
  • National Institute of Nursing Research (NINR)
  • University of California, San Francisco
Investigators  ICMJE
Principal Investigator: Benzi M Kluger, MD, MS University of Colorado, Denver
PRS Account University of Colorado, Denver
Verification Date November 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP